BioCentury
ARTICLE | Clinical News

SYN-004: Phase Ia data

January 26, 2015 8:00 AM UTC

Top-line data from 24 healthy volunteers in a double-blind, placebo-controlled, U.S. Phase Ia trial showed that single ascending doses of SYN-004 led to no clinically significant or relevant adverse e...